Plasma calprotectin as a biomarker of ultrasound synovitis in rheumatoid arthritis patients receiving IL-6 antagonists or JAK inhibitors

• Published in: Therapeutic advances in musculoskeletal disease Vol. 14; pp. 1759720 - 1759720X221114105
• Main Authors: Frade-Sosa, Beatriz, Ponce, Andrés, Inciarte-Mundo, José, Morlà, Rosa, Ruiz-Esquide, Viginia, Macías, Laura, Azuaga, Ana Belen, Ramirez, Julio, Cañete, Juan D., Yague, Jordi, Auge, Josep M., Gomez-Puerta, José A., Sanmarti, Raimon
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 2022; SAGE PUBLICATIONS, INC; SAGE Publishing
• Subjects: Biomarkers; Monoclonal antibodies; Musculoskeletal diseases; Original Research; Plasma; Rheumatoid arthritis; Ultrasonic imaging; acute phase proteins; leukocyte L1 antigen complex (calprotectin); ultrasonography; rheumatoid arthritis; biomarkers
• ISSN: 1759-720X; 1759-7218
• DOI: 10.1177/1759720X221114105

Objectives: To analyse the accuracy of plasma calprotectin in patients with rheumatoid arthritis (RA) receiving monoclonal antibodies against IL-6 receptors (anti-rIL-6) or JAK inhibitors (JAKis) in detecting ultrasound (US) synovitis and compare it with acute phase reactants [high-sensitivity C-reactive protein (hs-CRP) and ESR]. Methods: An observational cross-sectional study of RA patients receiving anti-rIL-6 (tocilizumab or sarilumab) or JAKi, (baricitinib or tofacitinib) was made. Plasma calprotectin for the diagnosis of US synovitis [synovial hypertrophy grade (SH) ⩾ 2 plus power Doppler signal (PD) ⩾ 1] was analysed using receiver operating characteristic curves (ROCs). The performance of ESR and hs-CRP was also studied. The three ROC curves were compared to determine which had the highest discriminatory power. Associations between plasma calprotectin and US scores were made using correlation analysis. Results: Sixty-three RA patients were included. Mean plasma calprotectin levels were significantly higher in patients with US synovitis than in those without (0.89 ± 0.85 vs 0.30 ± 0.12 μg/ml; p = 0.0003). A moderate correlation between calprotectin and all US scores (HS score Rho = 0.479; PD score Rho = 0.492; and global score Rho = 0.495) was found. The discriminatory capacity of plasma calprotectin showed an AUC of 0.795 (95% CI: 0.687–0.904). The AUC of hs-CRP and ESR was 0.721 and 0.564, respectively. hs-CRP serum levels showed a low positive correlation with the three US scores (Rho < 0.40). After analysis according to the drugs administered, the correlation disappeared in patients receiving anti-rIL-6. Conclusion: Plasma calprotectin may be a sensitive biomarker of synovial inflammation in RA patients treated with anti-rIL-6 or JAKi.